Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NS-863 in Healthy Subjects
jRCT2071230038Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NS-863 (6 arms), sponsored by Nippon Shinyaku. Primary endpoints: Pharmacokinetic parameters of NS-863, Safety of NS-863 and 1 more. Started Aug 2023; status: completed.
02
Drugs
NS-863
Beyond the preview
Go deeper on jRCT2071230038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230038.